Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 4, 2021PLoS ONEOpen Access

Plasma ACE2 predicts outcome of COVID-19 in hospitalized patients

View Full Paper
Ask AI
Bookmark
Share

Key result

High admission plasma ACE2 in COVID-19 patients was significantly associated with increased maximal illness severity within 28 days (OR 1.8).

Why the study?

SARS-CoV-2 binds to ACE2 to enter cells and cause COVID-19, prompting investigation into associations between plasma ACE2 levels and COVID-19 outcomes.

Does elevated plasma ACE2 predict worse clinical outcomes in hospitalized COVID-19 patients?

Population

306 COVID-19 positive and 78 COVID-19 negative patients in the MGH Emergency Department COVID-19 Cohort

Comparison

Plasma ACE2 levels and clinical outcomes

Design

Longitudinal cohort study

Follow-up

28 days

Authors

TKTue Wenzel KragstrupHSHelene Søgaard SinghIGIda Grundberg

Discussion

Loading...

Member takes

Overview

May support ACE2 as prognostic marker in COVID-19; leaves open validation and impact on management.

Study Design

Type

Cohort (n=384)

Multicenter

No

Structured PICO

Does elevated plasma ACE2 predict worse clinical outcomes in hospitalized COVID-19 patients?

P
Population
384 adult patients presenting to the emergency department with acute respiratory distress and clinical concern for COVID-19, followed for 28 days.
E
Exposure
Measurement of plasma ACE2 protein levels using Olink Explore 1536 platform at admission (day 0), day 3, and day 7.
O
Outcome
28-day outcome classification based on maximal illness severity (Acuity max, A1-A5: A1=Death, A2=Intubated, A3=Hospitalized with O2, A4=Hospitalized without O2, A5=Discharged).hard clinical

Main Result

Odds Ratio: 1.8 (95% CI 1.4–2.3)

p-value: p=<0.0001

Elevated admission plasma ACE2 levels in COVID-19 patients are significantly associated with increased 28-day illness severity, suggesting its potential value as a prognostic biomarker.

Limitations

  • Plasma ACE2 was measured as relative protein concentrations using NPX values, preventing determination of a clinical cut-off value.
  • Several continuous variables were categorized in the publicly available data set, decreasing statistical power.
  • Potentially important variables such as gender and treatment were not available.
  • Severity driven recruitment criteria (respiratory distress at emergency department) might have introduced a bias.
  • Causality of associations between plasma ACE2 and severity of COVID-19 disease cannot be drawn from this observational study.

Cite This Study

Kragstrup et al. (2021) conducted a cohort in COVID-19 (n=384). High admission plasma ACE2 vs. Lower admission plasma ACE2 was evaluated on Maximal illness severity within 28 days (OR 1.8, 95% CI 1.4-2.3, p=<0.0001). High admission plasma ACE2 in COVID-19 patients was significantly associated with increased maximal illness severity within 28 days (OR 1.8).

synapsesocial.com/papers/6a8583c8734852141cd4d3a9https://doi.org/10.1371/journal.pone.0252799
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Plasma ACE and ACE2 Levels Are Altered in Patients with COVID-192026
  2. 2Circulating ACE2 activity predicts mortality and disease severity in hospitalized COVID-19 patients2021 · 104 citations
  3. 3#2395 Elevated circulating ACE2 activity is related with a major COVID-19 severity2024
  4. 4The Role of Soluble ACE2 as a Prognostic Marker in Severe COVID-19: A Brief Meta-Analysis2022 · 5 citations
  5. 5Serum ACE2 Level is Associated With Severe SARS-CoV-2 Infection: A Cross-Sectional Observational Study2022 · 11 citations